FIELD: pharmaceutical.
SUBSTANCE: invention relates to a compound of formula (I) or pharmaceutically acceptable salt thereof, (I) where R1 is selected from H, F, Cl, Br, I, R101 and
where R101 is selected from following group consisting of phenyl, pyridyl, thienyl, furyl, thiazolyl, isothiazolyl, C1-6 alkyl, N,N-di(C1-6 alkyl)amino-(CH2)0-3, C3-4 cycloalkyl,
, where D101 is selected from CH2, O, S, NH and N(CH3); D102 represents CH2 or a single bond; and T101 is CH or N; and R101 is optionally substituted with 1, 2 or 3 F, Cl, Br, I, CN, CH3, CF3, CH3O or CF3O; m is 0, 1 or 2; R2 is selected from H, halogen or the following group optionally substituted by 1, 2 or 3 R01: C1-10 alkyl and C1-10 alkoxy; R3 is selected from the following group, optionally substituted with 1, 2 or 3 R01: 6-12-membered aryl, 6-12-membered arylalkylene and C3-6 cycloalkyl; R4 is C1-8 alkyl optionally substituted with 1 R01; R5 and R6 each independently represents H or C1-8 alkyl, where C1-8 alkyl is optionally substituted 1 F, Cl, Br, I, CN, OH or CF3; R5 and R6 together are optionally attached to one atom to form a 3 to 6-membered ring, optionally substituted with -OH; T1 and T2 each is independently selected from CH and N; X is selected from CH, -C(C6-12 aryl)-, -C(halogen)- and -C(C1-10 alkoxy)-; Y is selected from CH; R01 is selected from F, Cl, Br, I, CN, OH, CF3, CF3O, C1-8 alkoxy and C1-8 alkyl; "hetero" is a heteroatom or a group of heteroatoms selected from -NH-, -O-, -S- or N; where the number of heteroatoms or groups of heteroatoms is each independently selected from 0, 1, 2 or 3, which are used in the treatment of diseases, caused by mycobacteria, such as Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium avium and Mycobacterium marinum.
EFFECT: compound of formula or a pharmaceutically acceptable salt thereof.
11 cl, 110 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
BICYCLOSUBSTITUTED AZOPYRAZOLONE DERIVATIVES SALTS, METHOD FOR PREPARING AND USING THEM | 2010 |
|
RU2538977C2 |
SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | 2014 |
|
RU2671212C2 |
INHIBITOR OF EGFR AND PRODUCTION AND USE THEREOF | 2015 |
|
RU2702631C2 |
PYRIMIDINE COMPOUND WITH CONDENSED RINGS, ITS INTERMEDIATE COMPOUND, METHOD OF PRODUCING, COMPOSITION AND USE | 2016 |
|
RU2732576C2 |
PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS AN MTOR/PI3K INHIBITOR | 2015 |
|
RU2658912C1 |
PYRIDINIL- AND PYRAZINYL(AZA)INDOLSULFONAMIDES | 2019 |
|
RU2799321C2 |
2-AMINOPYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITION AND USE OF SAID COMPOUND | 2015 |
|
RU2704129C2 |
CALPAIN MODULATORS AND THEIR THERAPEUTIC USE | 2017 |
|
RU2773288C2 |
TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
Authors
Dates
2018-08-21—Published
2015-07-09—Filed